Biotech Values | Forum profile

rph: If you’re still following this board, I’d be interested in your comments on #msg-43805829. T.i.a. Dew

Medco is running a comparative effectiveness study of Plavix vs Effient trial, in which patients in the Plavix arm are genotyped for their CYP2C19 status. (http://clinicaltrials.gov/ct2/show/NCT00995514). Medco is trying to prove non-inferiority of Plavix in normal CYP2C19 metabolizers. If it works out for Medco, by the time Plavix goes of patent, simple genotyping test can distinguish those who can take cheap generics from those who cannot....

OT. No worries. I promise i won't ever correct your spelling.:) But someone is paid to correct PARD's spelling!

Budiodarone - No additional safety results from what I can see. I wonder what the p value for the 200 mg dose is. Having 3 doses would be a useful selling point over other drugs.

ARYX - additional budiodarone data http://finance.yahoo.com/news/Results-From-Phase-2b-Study-bw-2431070702.html?x=0&.v=1 Results From Phase 2b Study on Atrial Fibrillation Agent Reviewed at American Heart Association FREMONT, Calif.--(BUSINESS WIRE)--ARYx Therapeutics, Inc. (NASDAQ:ARYX - News), a biopharmaceutical company, announced that a review of the results of the Phase 2b clinical trial, PASCAL, testing the efficacy and safety of...

Short-term US interest rates turn negative By Michael Mackenzie in New York Financial Times November 20 2009 01:40 Short-term US interest rates turned negative on Thursday as banks frantically stockpiled government securities in order to polish their balance sheets for the end of the year. The development highlighted the continuing distortions in the financial system more than a year after Lehman Brothers’ failure triggered a global crisis....

[OT] the whole world this week has been talking about dollar carry trade and asset bubbles: 08:35 am : S&P futures vs fair value: -5.30. Nasdaq futures vs fair value: -11.00. [b]Europe's major bourses are trading lower amid reports that European Central Bank (ECB) President Trichet discussed withdrawing liquidity measures. Trichet indicated that any nonstandard measure that, if continued, would pose a threat to the achievement of...

nvd i really thought they would get more for the ambien spray. personally i think the pk profile is compelling and if marketed properly i woudl think it would sell regardless i thought NVD would do better and this is disappointing imo (especially given TSPT's deal)

In advance of this week's American Heart Association (AHA) Meeting (Nov 14-18, Orlando, FL), here are some expectations for companies under coverage at Wedbush PacGrow Life Sciences. Last night, The AHA released favorable results for ABT’s Niaspan study (ARBITER 6-HALTS, see below). Thoratec (THOR $29.41, OP, Mkt Cap $1.7B): Tue 11/17 - presentation of pivotal data on HeartMate II in Destination Therapy. - We believe that the HeartMate...

THanks as well for posting the repots. I noticed the Canaccord report [quote] Momenta intends to start a large, relatively expensive Phase 2b trial of M118 in ACS in 2010, which could significantly increase R&D spend if the program is not partnered. [/quote] I am pretty sure I heard (on the Lazard Call?) that they will NOT start this until they find a partner.